BR112023019323A2 - Composto, composição farmacêutica, e, métodos para o tratamento de obesidade, resistência à insulina, diabetes tipo ii ou atrofia muscular e para reduzir a perda de massa muscular em um indivíduo - Google Patents

Composto, composição farmacêutica, e, métodos para o tratamento de obesidade, resistência à insulina, diabetes tipo ii ou atrofia muscular e para reduzir a perda de massa muscular em um indivíduo

Info

Publication number
BR112023019323A2
BR112023019323A2 BR112023019323A BR112023019323A BR112023019323A2 BR 112023019323 A2 BR112023019323 A2 BR 112023019323A2 BR 112023019323 A BR112023019323 A BR 112023019323A BR 112023019323 A BR112023019323 A BR 112023019323A BR 112023019323 A2 BR112023019323 A2 BR 112023019323A2
Authority
BR
Brazil
Prior art keywords
methods
diabetes
loss
individual
compound
Prior art date
Application number
BR112023019323A
Other languages
English (en)
Inventor
Colin O'dowd
Frank Burkamp
Samuel Shane Rountree James
Duncan Helm Matthew
David Shepherd Steven
Kristopher Whitehead Steven
Timothy Harrison
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of BR112023019323A2 publication Critical patent/BR112023019323A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composto, composição farmacêutica, e, métodos para o tratamento de obesidade, resistência à insulina, diabetes tipo ii ou atrofia muscular e para reduzir a perda de massa muscular em um indivíduo. a presente invenção refere-se a compostos de fórmula (i) que são úteis como inibidores da atividade da protease específica da ubiquitina usp19. a presente invenção também se refere a composições farmacêuticas que compreendem esses compostos e a métodos para utilização desses compostos em terapia.
BR112023019323A 2021-03-24 2022-03-24 Composto, composição farmacêutica, e, métodos para o tratamento de obesidade, resistência à insulina, diabetes tipo ii ou atrofia muscular e para reduzir a perda de massa muscular em um indivíduo BR112023019323A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2104097.7A GB202104097D0 (en) 2021-03-24 2021-03-24 Pharmaceutical compounds
PCT/EP2022/057820 WO2022200523A1 (en) 2021-03-24 2022-03-24 Pharmaceuticals compounds as inhibitors of ubiquitin specific protease 19 (usp19)

Publications (1)

Publication Number Publication Date
BR112023019323A2 true BR112023019323A2 (pt) 2023-10-31

Family

ID=75689814

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019323A BR112023019323A2 (pt) 2021-03-24 2022-03-24 Composto, composição farmacêutica, e, métodos para o tratamento de obesidade, resistência à insulina, diabetes tipo ii ou atrofia muscular e para reduzir a perda de massa muscular em um indivíduo

Country Status (11)

Country Link
EP (1) EP4313295A1 (pt)
JP (1) JP2024511611A (pt)
KR (1) KR20230160901A (pt)
CN (1) CN117157285A (pt)
AU (1) AU2022244178A1 (pt)
BR (1) BR112023019323A2 (pt)
CA (1) CA3212236A1 (pt)
GB (1) GB202104097D0 (pt)
IL (1) IL307163A (pt)
MX (1) MX2023011012A (pt)
WO (1) WO2022200523A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840491B2 (en) * 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) * 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
WO2019067503A1 (en) * 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
GB201801562D0 (en) 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
JP2022512128A (ja) 2018-12-06 2022-02-02 アルマック・ディスカバリー・リミテッド 医薬化合物およびユビキチン特異的プロテアーゼ１９（ｕｓｐ１９）阻害剤としてのその使用
US20220016115A1 (en) 2018-12-06 2022-01-20 Almac Discovery Limited Usp19 inhibitors for use in therapy

Also Published As

Publication number Publication date
AU2022244178A1 (en) 2023-09-07
IL307163A (en) 2023-11-01
MX2023011012A (es) 2023-09-28
EP4313295A1 (en) 2024-02-07
JP2024511611A (ja) 2024-03-14
CN117157285A (zh) 2023-12-01
GB202104097D0 (en) 2021-05-05
WO2022200523A1 (en) 2022-09-29
CA3212236A1 (en) 2022-09-29
WO2022200523A9 (en) 2023-02-16
KR20230160901A (ko) 2023-11-24

Similar Documents

Publication Publication Date Title
ZA202109010B (en) Compounds and methods for the treatment of covid-19
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112015007182A2 (pt) inibidores de gdf-8
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0619839B8 (pt) derivados de 2-adamantiluréia, seu método de preparação e seus usos, composição farmacêutica, e kit
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
BR112014012815A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
BRPI0507198A (pt) derivados de bisariluréia
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.